StreetInsider.com News Articles

Canaccord Reiterates Buy Rating on Achieve Life Sciences (ACHV)

Tue, 14 Jul 2026 06:43:09 -0400

Canaccord analyst Gary Nachmann reiterated a Buy rating and $13.00 price target on Achieve Life Sciences (NASDAQ: ACHV).

The analyst commented: "ACHV's CRL for cytisinicline in smoking cessation (redacted version) was made available by FDA on Friday (link here), and overall it appears consistent with how management has been characterizing it. This is also noteworthy since it seemed that FDA had taken a pause publishing CRLs in general with some controversy around that, so it wasn't clear if/when the cytisinicline CRL would be published. ACHV had been indicating since mid-April that it was expecting to receive the CRL given cGMP-related observations

Form SCHEDULE 13G ACHIEVE LIFE SCIENCES, Filed by: Vivo Opportunity Fund Holdings, L.P.

Wed, 08 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260708/26747939.html

Form SCHEDULE 13G ACHIEVE LIFE SCIENCES, Filed by: Vivo Opportunity Fund Holdings, L.P.

Wed, 08 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260708/26747939.html

Form 8-K ACHIEVE LIFE SCIENCES, For: Jul 02

Mon, 06 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260706/26735487.html

Form 8-K ACHIEVE LIFE SCIENCES, For: Jul 02

Mon, 06 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260706/26735487.html

Achieve Life Sciences added to Russell 2000 index

Mon, 29 Jun 2026 08:32:30 -0400

Achieve Life Sciences, Inc. (Nasdaq: ACHV) has been added to the Russell 2000® Index, effective June 26, 2026, as part of the annual Russell U.S. Indexes reconstitution, according to a press release from the company. Achieve Life Sciences is also a member of the Russell 3000® Index.

The Russell 2000® Index tracks the performance of approximately 2,000 small-cap U.S. equities. The Russell 3000® Index measures the performance of approximately 3,000 of the largest U.S. stocks, representing roughly 98% of investable U.S. equities by market capitalization. Approximately $12.2 trillion in assets, as of June 30, 2025, are benchmarked against the Russell U.S.

Achieve Life Sciences added to Russell 2000 index

Mon, 29 Jun 2026 08:32:30 -0400

Achieve Life Sciences Joins Russell 2000® Index

Mon, 29 Jun 2026 08:30:00 -0400

SEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that it has been added to the Russell 2000® Index, effective June 26, 2026, as part of the Russell U.S. Indexes reconstitution. The Company is also a member of the Russell 3000® Index.

Approximately $12.2 trillion in assets, as of June 30, 2025, are benchmarked against the Russell U.S. Indexes, making them one of

Achieve Life Sciences Joins Russell 2000® Index

Mon, 29 Jun 2026 08:30:00 -0400

Approximately $12.2 trillion in assets, as of June 30, 2025, are benchmarked against the Russell U.S. Indexes, making them one of

Achieve Life Sciences Joins Russell 2000® Index

Mon, 29 Jun 2026 08:30:00 -0400

Approximately $12.2 trillion in assets, as of June 30, 2025, are benchmarked against the Russell U.S. Indexes, making them one of

Achieve Life Sciences Joins Russell 2000® Index

Mon, 29 Jun 2026 08:30:00 -0400

Approximately $12.2 trillion in assets, as of June 30, 2025, are benchmarked against the Russell U.S. Indexes, making them one of

Raymond James Resumes Achieve Life Sciences (ACHV) at Strong Buy

Fri, 26 Jun 2026 06:31:39 -0400

(Updated - June 26, 2026 6:31 AM EDT)

Raymond James analyst Ryan Deschner resumes coverage on Achieve Life Sciences (NASDAQ: ACHV) with a Strong Buy rating and a price target of $20.00.

The analyst commented: "We resume coverage of Achieve Life Sciences (ACHV) at Strong Buy with a $20 price target. Achieve is developing cytisinicline to potentially be the first new FDA-approved smoking cessation therapy in ~20 years. Supported primarily by three placebo-controlled Phase 2b (ORCA-1) and Phase 3 (ORCA-2 and ORCA-3) studies, cytisinicline’s safety, tolerability, and efficacy profile would make it the best-in-class therapy in smoking cessation if approved in 1H27

Raymond James Resumes Achieve Life Sciences (ACHV) at Strong Buy

Fri, 26 Jun 2026 06:31:39 -0400

(Updated - June 26, 2026 6:31 AM EDT)

Raymond James analyst Ryan Deschner resumes coverage on Achieve Life Sciences (NASDAQ: ACHV) with a Strong Buy rating and a price target of $20.00.

Increasing unusual call option volume: HLF WEN ACHV BMBL MIR MTUM

Fri, 26 Jun 2026 06:18:18 -0400

Increasing unusual call option volume: HLF WEN ACHV BMBL MIR MTUM

Canaccord Reiterates Buy Rating on Achieve Life Sciences (ACHV)

Tue, 23 Jun 2026 07:23:33 -0400

Canaccord analyst Gary Nachmann reiterated a Buy rating and $13.00 price target on Achieve Life Sciences (NASDAQ: ACHV).

The analyst commented: "ACHV received a CRL for cytisinicline in nicotine dependence that was very anticipated, consistent with the timeline it had flagged on 4/15/26 ahead of its 6/20/26 PDUFA. This action was expected given cGMP-related observations at ACHV's former third-party fill-finish manufacturing facility in France, which had received an OAI classification (matters were not specific to cytisinicline). Importantly, the FDA's feedback in the CRL confirmed that there were no deficiencies related to cytisinicline's clinical efficacy or safety, which was good to see.

H.C. Wainwright Reiterates Buy Rating on Achieve Life Sciences (ACHV)

Tue, 23 Jun 2026 06:51:11 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $12.00 price target on Achieve Life Sciences (NASDAQ: ACHV).

The analyst commented: "ACHV received the expected Complete Response Letter (CRL) for cytisinicline in smoking cessation, and we view the letter as supportive of our positive thesis on the stock, given we now have a clear and well-defined regulatory path centered on manufacturing and completion of labeling rather than product-specific approvability. The FDA did not identify any clinical efficacy or clinical safety deficiencies, which we believe is a significant positive and why we view today's CRL as a positive. While final label

FDA rejects Achieve Life Sciences drug application over manufacturing issues

Mon, 22 Jun 2026 08:30:56 -0400

Achieve Life Sciences, Inc. (Nasdaq: ACHV) announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for cytisinicline, a treatment for nicotine dependence.

The FDA cited manufacturing-related deficiencies at a third-party facility, which received an Official Action Indicated classification for general current Good Manufacturing Practice matters not specific to cytisinicline. The agency identified no deficiencies related to the clinical efficacy or safety of the drug.

The CRL also noted that final product labeling was not completed by the FDA's action date of June 20, 2026. Achieve had disclosed on April

FDA rejects Achieve Life Sciences drug application over manufacturing issues

Mon, 22 Jun 2026 08:30:56 -0400

The CRL also noted that final product labeling was not completed by the FDA's action date of June 20, 2026. Achieve had disclosed on April

FDA rejects Achieve Life Sciences drug application over manufacturing issues

Mon, 22 Jun 2026 08:30:56 -0400

The CRL also noted that final product labeling was not completed by the FDA's action date of June 20, 2026. Achieve had disclosed on April

FDA rejects Achieve Life Sciences drug application over manufacturing issues

Mon, 22 Jun 2026 08:30:56 -0400

The CRL also noted that final product labeling was not completed by the FDA's action date of June 20, 2026. Achieve had disclosed on April

Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA

Mon, 22 Jun 2026 08:30:00 -0400